Novo Nordisk-Hims weight loss drug partnership revenue misses Q3 2026 forecast

Hims & Hers recently inked a deal with Novo Nordisk to sell branded weight loss drugs. Given the weak guidance and subscriber revenue decline, the partnership is unlikely to generate the expected revenue boost in Q3 2026.

Implied probability (Yes)

70%